Investigational drug · Phase 2
Bimiralisib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Actinic Keratosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "Bimiralisib"
First trial start
2024
Apr 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bimiralisib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Actinic Keratosis
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Bimiralisib" as an intervention, largest first.
PIQUR Therapeutics AGIndustry
NCT02249429 · 53 participants · Start May 2015 · Primary completion Sep 11, 2018
Drug: bimiralisib · For: Lymphoma, Malignant
Sites: New York, New York; Banja Luka, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina · 12 sites in all
- Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic KeratosisCompleted
TORQURIndustry
NCT06319794 · 46 participants · Start Apr 2, 2024 · Primary completion Jun 24, 2025
Drug: Bimiralisib; Bimiralisib · For: Actinic Keratosis
Sites: Basel, Switzerland; Lausanne, Switzerland
PIQUR Therapeutics AGIndustry
NCT02669511 · 21 participants · Start Nov 12, 2015 · Primary completion Jan 12, 2018
Drug: PQR309 · For: Primary Central Nervous System Lymphoma
- Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function MutationsTerminated
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03740100 · 8 participants · Start Jan 25, 2019 · Primary completion Aug 5, 2020
Drug: Bimiralisib · For: HNSCC
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Bimiralisib suppresses proliferation and migration of gastric cancer cells via PI3K/mTOR pathway inhibition.
Noh YJ, Jeong HE, Cha SH, et al. · Korean J Physiol Pharmacol 2026
- Design, synthesis, in vitro cytotoxic activity, and in silico studies of symmetrical chlorophenylamino-s-triazine derivatives.
Canh Pham E, Nguyen ST, Thi Le KA, et al. · RSC Adv 2025
- Quantitative Analysis of Bimiralisib in Dried Blood Spots of Mouse Blood Using a Validated LC-MS/MS Method: An Application to Pharmacokinetic Study.
Zakkula A, Haque MA · Biomed Chromatogr 2025
- A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Janku F, Choong GM, Opyrchal M, et al. · Cancers (Basel) 2024
- Recent biological applications of heterocyclic hybrids containing s-triazine scaffold.
Ali MI, Naseer MM · RSC Adv 2023
- Correction: Wind et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers 2022, 14, 1510.
Wind SS, Jansen MAA, Rijsbergen M, et al. · Cancers (Basel) 2023
Also in development for Actinic Keratosis
Sun Pharmaceutical Industries, Inc. · Actinic Keratosis
- HW211026Phase 21 trial
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Actinic Keratosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.